Corporate Overview

Shattuck is a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of cancer and autoimmune disease. Compounds derived from Shattuck’s ARC platform simultaneously inhibit checkpoint molecules and activate costimulatory molecules within a single therapeutic. The company’s lead program, SL-172154 (SIRPα-Fc-CD40L), is designed to block the CD47 immune checkpoint and simultaneously activate the CD40 receptor, a member of the tumor necrosis factor superfamily, is being evaluated in multiple Phase 1 clinical trials. Additionally, the company is advancing its second proprietary platform, Gamma Delta T Cell Engagers (GADLEN™). Compounds derived from our GADLEN platform represent a novel approach to targeting gamma delta t-cells and are designed to bridge gamma delta T cells to tumor antigens for the treatment of cancer.

Latest News

View all news

Featured Presentation

View All Presentations

Latest Events

View All Events

Latest Quarterly Reports

View All Financial Reports